S

Structure Therapeutics Inc
NASDAQ:GPCR

Watchlist Manager
Structure Therapeutics Inc
NASDAQ:GPCR
Watchlist
Price: 66.74 USD -4.63% Market Closed
Market Cap: 4B USD

Relative Value

There is not enough data to reliably calculate the relative value of GPCR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GPCR Relative Value
Base Case
Not Available
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-21.1
Median 5Y
-21.1
Industry
21.7
Forward
-15.1
vs History
vs Industry
Median 3Y
-22
Median 5Y
-22
Industry
16.6
vs History
vs Industry
Median 3Y
-21.7
Median 5Y
-21.7
Industry
22.5
vs History
41
vs Industry
52
Median 3Y
2.8
Median 5Y
2.8
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-11.5
Industry
13.1
Forward
-11.6
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-11.5
Industry
16.6
Forward
-11.4
vs History
vs Industry
Median 3Y
-15.1
Median 5Y
-15.1
Industry
15.8
vs History
vs Industry
Median 3Y
-14.7
Median 5Y
-14.7
Industry
19.1
vs History
22
vs Industry
4
Median 3Y
82.3
Median 5Y
82.3
Industry
1.9

Multiples Across Competitors

GPCR Competitors Multiples
Structure Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Structure Therapeutics Inc
NASDAQ:GPCR
4B USD 0 -19.2 -13 -12.9
US
Eli Lilly and Co
NYSE:LLY
936.3B USD 15.8 51 34.2 36.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
490.7B USD 5.3 19.6 16 20.7
CH
Roche Holding AG
SIX:ROG
255.9B CHF 4.2 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.8 29.7 108 158.1
CH
Novartis AG
SIX:NOVN
201.7B CHF 4.5 17.4 11.1 14.3
US
Merck & Co Inc
NYSE:MRK
242.2B USD 3.8 12.7 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13.2 9.1 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
S
Structure Therapeutics Inc
NASDAQ:GPCR
Average P/E: 23.2
Negative Multiple: -19.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
S
Structure Therapeutics Inc
NASDAQ:GPCR
Average EV/EBITDA: 437.4
Negative Multiple: -13
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.2
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.1
6%
1.8
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
S
Structure Therapeutics Inc
NASDAQ:GPCR
Average EV/EBIT: 1 878.3
Negative Multiple: -12.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.3
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3